Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is Milestone Pharmaceuticals (MIST) Stock Down -15.38% Today?

Why Is Milestone Pharmaceuticals (MIST) Stock Down -15.38% Today?

Key Takeaways

  • MIST fell 15.38% to $0.44 in Monday morning trading, extending a two-session collapse of roughly 33% and pushing the shares below their prior 52-week low of $0.50.
  • The immediate catalyst was a coordinated round of post-earnings price target cuts, with Piper Sandler, TD Cowen, Wells Fargo and H.C. Wainwright all reducing their targets on the stock.
  • Friday's third-quarter report showed a revenue beat driven largely by a one-time $2 million license payment, while CARDAMYST net product sales reached only $963,000 against $24.2 million of SG&A.
  • Management announced a roughly 30% operating expense reduction and confirmed the departures of its CFO and CMO, signaling a slower commercial ramp than originally modeled.
  • Broader conditions amplified the selling: major indices opened sharply lower Monday and speculative small-cap biotechnology names were under broad pressure.
  • News Significance Score: 58/100 — Moderate news from post-earnings target cuts, with the decline about four times the typical daily move.
  • Traders are watching prescription trends into the seasonally disruptive first quarter of 2027, Medicare Part D coverage negotiations, and the fully funded ReVeRA-301 Phase 3 readout expected in the second half of 2028.
  • For deeper detail on Price Targets, Earnings and Forecast data, explore the dedicated ticker pages.
  • Readers can also review the curated Trending AI Robots page to see which automated strategies are performing best in the current tape.

Milestone Pharmaceuticals Stock Slides to a Fresh 52-Week Low

Milestone Pharmaceuticals Inc. (MIST) is a Montreal- and Charlotte-based biopharmaceutical company that commercializes CARDAMYST (etripamil), a self-administered nasal spray approved in the United States for acute episodes of paroxysmal supraventricular tachycardia (PSVT), and is developing the same drug for atrial fibrillation with rapid ventricular rate. Its shares traded at $0.44 early Monday, down 15.38% from Friday's close of $0.52, after touching an intraday low of $0.41 — a fresh 52-week low for a stock already down roughly 78% year to date.

The move extends Friday's 20.6% decline and reflects a clear, verifiable catalyst: a broad round of analyst estimate resets following the company's third-quarter results, layered on top of a visibly softer-than-expected launch trajectory for its only commercial product.

Analyst Price Targets Cut Sharply After the Q3 Print

The most direct driver of Monday's selling was a cluster of research notes published between Sunday evening and Monday morning. Piper Sandler cut its target to $3 from $7 while maintaining an Overweight rating, citing softer CARDAMYST sales and now modeling U.S. net product sales of $3.39 million for 2026 and $12.5 million for 2027. TD Cowen lowered its target to $5 from $8 with a Buy rating, and Wells Fargo reduced its target to $4 from $7, pointing to a slower-than-expected inflection point and narrower Medicare coverage. H.C. Wainwright trimmed its target to $6 from $8.

The magnitude of the reductions is significant. Piper Sandler's cut alone represented a 57% reduction in expected value, and the clustering of four reductions within a single session removed much of the near-term upside framing that had supported the stock. Notably, all four firms retained constructive ratings, and their targets remain far above the current share price — a gap that itself highlights how far sentiment has swung relative to published models.

A Launch Growing Slower Than Planned

Friday's report was superficially strong: revenue of $2.96 million beat consensus near $1.2 million, and the loss of $0.18 per share came in ahead of the $0.22 expected. But the composition of that beat undermined confidence. Of total revenue, $2.0 million came from license and other income tied to Everest Medicines' approval of etripamil in China. Net CARDAMYST product revenue was $963,000 — up 73% sequentially, but a small figure against $24.2 million in selling, general and administrative expense, which more than tripled from $7.9 million a year earlier.

The net loss widened to $25.8 million from $11.9 million. Operating data improved directionally, with roughly 1,800 prescriptions in the quarter, about 750 unique prescribers and commercial coverage reaching roughly two-thirds of covered lives. Yet management replaced prior language about an accelerating second-half "tipping point" with talk of "steady growth," acknowledged physician inertia as a core obstacle, and warned of a possible flattening or dip in prescriptions in the first quarter of 2027 as insurance deductibles reset.

Cost Cuts and Management Turnover

Alongside the results, Milestone announced a roughly 30% reduction in operating expenses — including internalizing its approximately 45-person contracted sales force — with about $2 million in one-time charges and completion targeted by the first quarter of 2027. The plan extends the cash runway into late 2028, past the ReVeRA-301 readout. Investors, however, focused on the accompanying disclosure that Chief Financial Officer Amit Hasija and Chief Medical Officer David Bharucha had departed, a combination that introduces execution uncertainty at precisely the moment the company is asking the market to trust a longer, slower commercial arc.

Market Context and Trading Activity

Volume was elevated. Roughly 1.4 million shares changed hands in the first hour of Monday's session against a 20-session average near 1 million, with most of the heaviest blocks printing in the opening 30 minutes as the stock gapped down from Friday's $0.52 close to an opening print near $0.50 before breaking to $0.41.

The move was amplified by a risk-off tape. Major U.S. indices opened sharply lower Monday, and small-cap biotechnology was among the weakest segments, with the sector having already lagged the prior week's broader rally. Speculative, sub-$1 biotech names traded lower across the board, meaning part of Monday's decline reflects sector and liquidity conditions rather than company-specific news alone. Technically, the stock broke decisively below its prior 52-week low of $0.50 and is trading well beneath its 50- and 200-day moving averages, a pattern consistent with persistent distribution.

News Significance Score

The score runs from 0, meaning no meaningful news and a price move that is normal for the stock, to 100, meaning transformative news and an extreme, rare move. This event earns 58 out of 100.

The verified news is moderate in strength: a mixed earnings report featuring a low-quality revenue beat, a strategic cost reset, two senior management departures and four simultaneous price target reductions. That is material for a company with a market capitalization near $60 million, but it is not transformative. The price move was unusual but not extraordinary by this stock's standards — roughly 3.8 times its typical daily absolute move of about 4%, with only one of the prior 69 sessions producing a larger swing. Moderate news plus a clearly outsized, elevated-volume decline combines into a mid-range score.

What Comes Next for MIST

Attention now shifts to the durability of the CARDAMYST ramp. Investors will watch monthly prescription data for evidence that the internalized sales force can stabilize growth, and any commentary on Medicare Part D and CVS Caremark national coverage, both of which remain unresolved swing factors. The next scheduled quarterly report is expected in March 2027, and management has already flagged the possibility of a first-quarter prescription dip.

The balance sheet is the other focal point. With $145.4 million in cash, an $82.8 million royalty financing obligation and a small shareholders' deficit, the company has bought time rather than flexibility, and the 30% cost program must be executed cleanly. Beyond that, the ReVeRA-301 Phase 3 trial in AFib-RVR — a substantially larger potential market — remains the central binary event, with data expected in the second half of 2028. Continued sector weakness toward cash-burning small caps would remain a headwind regardless of operating progress.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated view of automated trading strategies that are outperforming in current market conditions. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers are surfaced in this section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the featured lineup rotates as conditions change. Reviewing the current leaders can help traders compare approaches against their own risk parameters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MIST

MIST in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 13, 2026

MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 37 cases where MIST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for MIST's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +7.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for MIST turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for MIST entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.213) is normal, around the industry mean (3.498). P/E Ratio (-1.174) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer and manufacturer of cardiovascular medicines

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
1111 Dr. Frederik-Phillips Boulevard
Phone
+1 514 336-0444
Employees
38
Web
https://www.milestonepharma.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.